Transcript Folie 1 - Arginine Cardio

Arginine Cardio: Evidence-based reduction of blood pressure (1)
L-Arginine is the precursor of Nitric Oxide
L-Citrulline potentiates the bioavailability of L-arginine
Arginine Cardio is the L-Arginine supplement that has the highest L-citrulline
Content
Nitric Oxide causes vasodilation and thereby reduces blood pressure.
Author: Dr. Rainer Böger
Page 1
© Arginine Benefits LLC, 2013
Arginine Cardio: Evidence-based reduction of blood pressure (2)
L-Arginine is not being marketed by pharmaceutical industry
with a multi million dollar budget for promotion.
Clinical trials with L-arginine to lower blood pressure have been performed
by independent academic research institutions, with small research budgets.
Therefore, patient numbers in clinical trials with L-arginine
are comparatively small.
However, there is a recent meta-analysis summarizing clinical trials
with L-arginine.
Author: Dr. Rainer Böger
Page 2
© Arginine Benefits LLC, 2013
Arginine Cardio: Evidence-based reduction of blood pressure (3)
11 randomized, double-blind, placebo-controlled trials involving 387 participants
with oral L-arginine intervention ranging from 4 to 24 g/d
[…] Compared with placebo, L-arginine intervention significantly lowered
systolic blood pressure by 5.39 mm Hg (95% CI −8.54 to −2.25, P = .001) and
diastolic BP by 2.66 mm Hg (95% CI −3.77 to −1.54, P = .001).
Dong et al.; American Heart Journal 2011
Author: Dr. Rainer Böger
Page 3
© Arginine Benefits LLC, 2013
L-Arginine better
Placebo better
Dong et al.; American Heart Journal 2011
Author: Dr. Rainer Böger
Page 4
© Arginine Benefits LLC, 2013
L-Arginine better
Placebo better
Dong et al.; American Heart Journal 2011
Author: Dr. Rainer Böger
Page 5
© Arginine Benefits LLC, 2013
Dong et al.; American Heart Journal 2011
Author: Dr. Rainer Böger
Page 6
© Arginine Benefits LLC, 2013
Arginine Cardio: Evidence-based reversal of atherosclerosis (1)
Nitric Oxide has been known to protect from atherosclerosis ever since
the Nobel Prize for Medicine was awarded for this finding in 1998.
L-Arginine is the precursor of Nitric Oxide.
Animal experiments have unequivocally proven in different models and in
various laboratories around the world that L-arginine can reverse atheroslcerosis.
Whilst no big, multinational studies could be performed with L-arginine due to
lack of funding from public sources, multiple studies have shown reversal of
endothelial dysfunction, the early clinical sign of atherosclerosis, by L-arginine.
We have a collection of case reports that show reversal of atherosclerotic plaque
in humans during a few months of L-arginine intake.
Author: Dr. Rainer Böger
Page 7
© Arginine Benefits LLC, 2013
Study A: Prevention of Plaque Build-Up
Design:
Cholesterol + L-Arginine
Cholesterol
Control
8
weeks
Results:
Cholesterol
Carotid intimal plaque area
[% of total intima]
0
60
55
50
45
40
35
30
25
20
15
10
5
0
A. carotis
*
#
(0)
CONTROL CHOLESTEROL
Cholesterol; treated with L-arginine
CHOL.
+ L-ARGININE
Böger et al., Atherosclerosis 1995; 117: 273 – 284
Author: Dr. Rainer Böger
Page 8
© Arginine Benefits LLC, 2013
Study B: Stopping the Progression of Plaque Build-Up
Cholesterol + L-Arginine
Design:
Cholesterol
Cholesterol
Cholesterol + Lovastatin
Control
Control
0
Intimal plaque area
(carotid artery) [%]
Results:
4
10
16
weeks
50
„Dietary L-arginine completely suppressed
the aggravation of intimal plaque formation
during the second part of the study
Lovastatin treatment significantly reduced
the progression of plaque formation but did
not completely block it.“
40
30
-92%
20
10
0
0
4
16
weeks
Böger et al., Circulation 1997; 96: 1282-1290
Author: Dr. Rainer Böger
Page 9
© Arginine Benefits LLC, 2013
Study C: Reversal of Pre-Existing Plaque
Design:
Cholesterol
Cholesterol
Cholesterol + L-Arginine
Cholesterol
0
Intimal plaque area
(carotid artery) [%]
Results:
10
18
23
weeks
75
„This is the first demonstration that
restoration of NO activity can induce
regression of preexisting intimal lesions
and provides evidence that L-arginine therapy
may be of potential clinical benefit “
60
45
30
15
0
0
10
14
18
23
weeks
Candipan et al., Arterioscler. Thromb. Vasc. Biol. 1996; 16: 44-50
Author: Dr. Rainer Böger
Page 10
© Arginine Benefits LLC, 2013
Author: Dr. Rainer Böger
Page 11
© Arginine Benefits LLC, 2013
Author: Dr. Rainer Böger
Page 12
© Arginine Benefits LLC, 2013
Author: Dr. Rainer Böger
Page 13
© Arginine Benefits LLC, 2013